Document is current

Article History

Received: 19 September 2024

Accepted: 14 January 2025

First Online: 3 February 2025

Declarations

:

: All participants signed the informed consent for the study previously approved by the Research Ethics Committee of the Hospital Clínic of Barcelona (HCB/2015/0752). Furthermore, the study was performed in accordance with the Declaration of Helsinki (Fortaleza, Brazil, October 2013). As specified in the informed consent form, data were collected from participants until revocation of it, death or completion 10 years after SVR.

: No applicable.

: NG: received congress registration from Eisai; GI: received travel grants from Bayer; CB: none; NL: received consultancy fees from Bayer, Universal DX and AstraZeneca, speaker fees from Roche and AstraZeneca, travel funding from Bayer and congress registration from Eisai; AP: none; VS: received travel grants from Bayer and consultancy fees from LEO Pharma; SL: received consultancy and speaker fees from Gilead and Abbvie and grants from Gilead; ZM: received consultancy fees from Gilead, Abbvie, Alexion, Orphalan and Deep Genomics; speaker fees from Gilead, Abbvie and Orphalan. Research grants from Gilead; RV: none; IN: none; AD: received speaker fees and travel grants from Bayer; EB: none; AGC: received speaker fees from BTG and Terumo; AD: received speaker fees and travel grants from Bayer; MSZ: received speaker fees from Bayer and travel grants from Bayer, BTG, MSD-Eisai and Roche; CF: none; SMM: received speaker fees from Bayer and travel grants from Bayer, MDS and Eisai; CA: received speaker fees, travel and research grants from Bayer, BTG and Terumo; consultancy from Roche; LB: none; JR: has consulted for Roche and received speaker fees from Bayer and Roche and travel grants from Bayer; AS: none; AF: received lecture fees from Gilead, Boston Scientific, Roche, AstraZeneca and MSD; consultancy fees from AstraZeneca, Roche, SIRTEX, AB Exact Science, Taiho and Guerbert; FT: DSMB fees from Basiela Pharmaceutica International, ArchivelFarma, S.L, Daiichi-Sankyo Pharma Development, ArQule and Rovi; speaker fees from Bayer and educational and training fees from Janssen and Ferrer; JR: Novartis, Lilly, LETIPharma, Merck Sharp & Dohme de España, ViforFresenius, Astra Zeneca and Boehringer Ingelheim Boehringer Ingelheim lecture fees educational outside the submitted work; JB: has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG- Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, Sanofi; received research/educational grants from Bayer; paid conferences from Bayer, BTG, AstraZeneca and Ipsen; andlecture fees from Bayer-Shering Pharma, BTG-Biocompatibles, Eisai, Terumo, Sirtex and Ipsen; AMM: Consultant for TARGET RWE; XF: acted as advisor for Gilead; MR: has served as a consultant or on advisory boards and/or received travel support from Bayer, BMS, Roche, Ipsen, AstraZeneca, Eisai, Geneos Therapeutics, UniveralDx, MSD and Lilly, lecture fees from Bayer, BMS, Gilead, AstraZeneca, ROCHE and Lilly and Institutional research grants from Bayer and Ipsen.